ВОПРОСЫ КЛАССИФИКАЦИИ, КЛИНИЧЕСКАЯ КАРТИНА И БАЗИСНАЯ ТЕРАПИЯ ЮВЕНИЛЬНОЙ СКЛЕРОДЕРМИИ
https://doi.org/10.14412/1995-4484-2015-214-219
Аннотация
Представлены современные сведения о классификации, клинической картине, диагностике и лечении склеродермии у детей по данным литературы и собственных исследований.
Об авторах
М. К. ОсмининаРоссия
Контакты: Мария Кирилловна Осминина;
Н. А. Геппе
Россия
Список литературы
1. Никитина МН. Ограниченная склеродермия у детей. Вопросы клиники, патогенеза и лечения. Автореф. дисс. … д-ра мед.наук. Москва;1980 [Nikitina MN. Ogranichennaya sklerodermiya u detei. Voprosy kliniki, patogeneza i lecheniya. Avtoref. diss. … d-ra med.nauk [Limited scleroderma in children. Questions clinic, pathogenesis and treatment: Dr. Diss. (Med. Sci.)]. Moscow; 1980].
2. Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008;20(5):601–7. doi: 10.1097/BOR.0b013e328309a5eb
3. Pelkonen PM, Jalanco HJ, Lantto RK, et. al. Incidence of systemic connective tissue disease in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143–6.
4. Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Irelands. Arthritis Care Res (Hoboken). 2010;62(2):213–8. doi: 10.1002/acr.20070
5. Atzeni F, Bardoni A, Cutolo M, et. al. Localized and systemic forms of scleroderma in adults and children. Clin Exper Rheumatol. 2006:24(1 Suppl 40):36–45.
6. Foeldvari I. Juvenile systemic sclerosis. In: Varga J, Denton CP, Wigley FM, editors. Scleroderma: from pathogenesis to comprehensive management. New York: Springer Science+Business Media, LLC; 2012. 93 p.
7. Martini G, Foelvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients. Arthritis Rheum. 2006;54(12):3971–8. doi: 10.1002/art.22207
8. Zulian F, Athreya B, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. J Rheumatol. 2006;45(5):614–20. doi: 10.1093/rheumatology/kei251
9. Cassidy TJ, Petty RE. Text book of Pediatric Rheumatology. Toronto: Elsevier Saunders Сompany; 2002. 505 p.
10. Уварова НН. Клиническая картина и течение системной склеродермии у детей. Автореф. дисс. … д-ра мед. наук. Москва; 1989 [Uvarova NN. Klinicheskaya kartina i techenie sistemnoi sklerodermii u detei. Avtoref. diss. … d-ra med. nauk [The clinical picture and course of systemic sclerosis in children: Dr. Diss. (Med. Sci.)]. Moscow; 1989].
11. Гусева НГ. Системная склеродермия и псевдосклеродермические синдромы. Москва: Медицина;
12. С.25. [Guseva NG. Sistemnaya sklerodermiya i psevdosklerodermicheskie sindromy [System sklerodermiya and psevdosklerodermichesky syndromes]. Moscow: Meditsina; 1993. P. 25.]
13. Scalapino K, Arkachaisri T, Lucas M, et al. Childhood-onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult-onset disease. J Rheumatol. 2006;33(5):1004–13.
14. Zulian F, Woo P, Athrea B, et al. The Pediatric European Society American College of Rheumatology European League Against Rheumatism Provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203–12. doi: 10.1002/art.22551
15. Athrea B. Juvenile scleroderma. Curr Opin Rheumatol. 2002;14(5):553-61. doi: 10.1097/00002281-200209000-00013
16. Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am. 2008;34(1):239–55. doi: 10.1016/j.rdc.2007.11.004
17. Школьникова МА, Алексеева ЕА, редакторы. Клинические рекомендации по детской кардиологии и ревматологии. Москва: ООО «М-Арт»; 2011. 397 с. [Shkol'nikova MA, Alekseeva EA, editors. Klinicheskie rekomendatsii po detskoi kardiologii i revmatologii [Clinical guidelines on pediatric cardiology and rheumatology]. Moscow: OOO «M-Art»; 2011. 397 p.].
18. Карташева ВИ. Нефропатии при ревматических заболеваниях у детей. Вопросы современной педиатрии. 2004;(5):65–9. [Kartasheva VI. Nefropatii pri revmaticheskikh zabolevaniyakh u detei. Voprosy sovremennoi pediatrii. 2004;(5):65–9. (In Russ.)].
19. Shapiro LS, Prince RK, Buckingham RB, et al. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects. J Rheumatol. 1983;10(2):316–8.
20. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial,followed by a 24 week observation trial. Br J Rheumatol. 1996;35(4):364–72. doi: 10.1093/rheumatology/35.4.364
21. Pope JE, Bellamy N, Seilbord JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–8. doi: 10.1002/1529–0131(200106)44:6<1351::AIDART227>3.0.CO;2-I
22. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217–20. doi: 10.1136/annrheumdis-2012-202657
23. Seyger MM, van den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998;39;220–5. doi: 10.1016/S0190-9622(98)70079-9
24. Zulian F, Martini G, Vallongo C, et al. Methotrexate in juvenile localized scleroderma: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. doi: 10.1002/art.30264
25. Li SC, Feldman BM, Higgins GC, et al. Treatment of pediatric localized scleroderma: results of a survey of North American pediatriс rheumatologists. J Rheumatol. 2010;37(1):254–7.
26. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33(1):91–4. doi: 10.1002/art.1780330112
27. Tukova J, Chadek J, Nemkova D, et al. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exper Rheumatol. 2009;27(6):1047–53.
28. Klein A, Kaul I, Foeldvari I, et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res. 2012;64(9):1349–56. doi: 10.1002/acr.21697
29. Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: A road map toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res. 2012;64(8):1175–85. doi: 10.1002/acr.21687
30. Осминина МК, Лыскина ГА, Амосова ЕП и др. Д-пеницилламин в лечении ограниченных форм ювенильной склеродермии. Педиатрия. 2008;(4):97–9. [Osminina MK, Lyskina GA, Amosova EP, et al. D-penitsillamin v lechenii ogranichennykh form yuvenil'noi sklerodermii. Pediatriya. 2008;(4):97–9. (In Russ.)].
31. Lo CY, Shyur SD, Chu SH, et al. Juvenile scleroderma: experience in one institution. Asian Pac J Allergy Immunol. 2010;28(4):279–86.
Рецензия
Для цитирования:
Осминина М.К., Геппе Н.А. ВОПРОСЫ КЛАССИФИКАЦИИ, КЛИНИЧЕСКАЯ КАРТИНА И БАЗИСНАЯ ТЕРАПИЯ ЮВЕНИЛЬНОЙ СКЛЕРОДЕРМИИ. Научно-практическая ревматология. 2015;53(2):214-219. https://doi.org/10.14412/1995-4484-2015-214-219